Breakthrough Strategy for Advanced Cancer

A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. A laboratory study conducted at Leiden University Medical Center (LUMC) in the Netherlands has found that immunotherapy can be efficiently combined with photodynamic therapy (PDT) to eradicate established tumors. The approach results in strong local tumor destruction and a

Male and female drinking patterns becoming more alike in the US

In the United States, and throughout the world, men drink more alcohol than women.  But a recent analysis by scientists at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, indicates that longstanding differences between men and women in alcohol consumption and alcohol-related

Following Two Years of Work With The FDA, 23andMe Announces New Customer Experience As Personal Genome Service

23andMe, Inc., the leading personal genetics company, today announced the launch of their new Personal Genome Service (PGS). Following two years of work with the FDA, extensive user comprehension testing and a complete redesign, 23andMe is launching an entirely new experience that includes carrier status, wellness, trait and ancestry reports. Experience

Lancet Oncology Commission Report Insists For Global Approach to Radiotherapy

Increasing access to radiotherapy worldwide through greater investment could save millions of lives, according to The Lancet Oncology Commission's report presented at the 2015 European Cancer Congress in Vienna, Austria, and published in The Lancet Oncology. The Commission's results were presented here yesterday at the 2015 annual meeting of the

Cancer Patients Report Improved Function And Well-Being With Telotristat Etiprate Therapy By Lexicon

Lexicon Pharmaceuticals, Inc.'s (Nasdaq: LXRX) telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study presented at the 2015 Neuroendocrine

Positive Preclinical Data on VAL-083 Presented by DelMar Pharmaceuticals for Ovarian Cancer

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced that yesterday it presented positive preclinical data demonstrating the promising potential of its lead product candidate VAL-083 (dianhydrogalactitol) as a treatment for ovarian cancer.